tetano
Editor, Senior Moderator
PLoS One
. 2022 Sep 9;17(9):e0272840.
doi: 10.1371/journal.pone.0272840. eCollection 2022.
Procalcitonin as a predictive marker in COVID-19: A systematic review and meta-analysis
Amit Kumar[SUP] 1 [/SUP], Era Karn[SUP] 2 [/SUP], Kiran Trivedi[SUP] 3 [/SUP], Pramod Kumar[SUP] 4 [/SUP], Ganesh Chauhan[SUP] 5 [/SUP], Aradhana Kumari[SUP] 4 [/SUP], Pragya Pant[SUP] 6 [/SUP], Murali Munisamy[SUP] 7 [/SUP], Jay Prakash[SUP] 8 [/SUP], Prattay Guha Sarkar[SUP] 9 [/SUP], Kameshwar Prasad[SUP] 10 [/SUP], Anupa Prasad[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 has emerged as a global pandemic causing millions of critical cases and deaths. Early identification of at-risk patients is crucial for planning triage and treatment strategies.
Methods and findings: We performed this systematic review and meta-analysis to determine the pooled prognostic significance of procalcitonin in predicting mortality and severity in patients with COVID-19 using a robust methodology and clear clinical implications.
Design: We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane Handbook for Systematic Reviews of Interventions guidelines. We included thirty-two prospective and retrospective cohort studies involving 13,154 patients.
Results: The diagnostic odds ratio of procalcitonin for predicting mortality were estimated to be 11 (95% CI: 7 to 17) with sensitivity, specificity, and summary area under the curveof 0.83 (95% CI: 0.70 to 0.91), 0.69 (95% CI: 0.58 to 0.79), and 0.83 (95% CI: 0.79 to 0.86) respectively. While for identifying severe cases of COVID-19, the odds ratio was 8.0 (95% CI 5.0 to 12.0) with sensitivity, specificity, and summary area under the curve of 0.73 (95% CI 0.67 to 0.78), 0.74 (0.66 to 0.81), and 0.78 (95% CI 0.74 to 0.82) respectively.
Conclusion: Procalcitonin has good discriminatory power for predicting mortality and disease severity in COVID-19 patients. Therefore, procalcitonin measurement may help identify potentially severe cases and thus decrease mortality by offering early aggressive treatment.
. 2022 Sep 9;17(9):e0272840.
doi: 10.1371/journal.pone.0272840. eCollection 2022.
Procalcitonin as a predictive marker in COVID-19: A systematic review and meta-analysis
Amit Kumar[SUP] 1 [/SUP], Era Karn[SUP] 2 [/SUP], Kiran Trivedi[SUP] 3 [/SUP], Pramod Kumar[SUP] 4 [/SUP], Ganesh Chauhan[SUP] 5 [/SUP], Aradhana Kumari[SUP] 4 [/SUP], Pragya Pant[SUP] 6 [/SUP], Murali Munisamy[SUP] 7 [/SUP], Jay Prakash[SUP] 8 [/SUP], Prattay Guha Sarkar[SUP] 9 [/SUP], Kameshwar Prasad[SUP] 10 [/SUP], Anupa Prasad[SUP] 4 [/SUP]
Affiliations
- PMID: 36084093
- DOI: 10.1371/journal.pone.0272840
Abstract
Background: Coronavirus disease 2019 has emerged as a global pandemic causing millions of critical cases and deaths. Early identification of at-risk patients is crucial for planning triage and treatment strategies.
Methods and findings: We performed this systematic review and meta-analysis to determine the pooled prognostic significance of procalcitonin in predicting mortality and severity in patients with COVID-19 using a robust methodology and clear clinical implications.
Design: We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane Handbook for Systematic Reviews of Interventions guidelines. We included thirty-two prospective and retrospective cohort studies involving 13,154 patients.
Results: The diagnostic odds ratio of procalcitonin for predicting mortality were estimated to be 11 (95% CI: 7 to 17) with sensitivity, specificity, and summary area under the curveof 0.83 (95% CI: 0.70 to 0.91), 0.69 (95% CI: 0.58 to 0.79), and 0.83 (95% CI: 0.79 to 0.86) respectively. While for identifying severe cases of COVID-19, the odds ratio was 8.0 (95% CI 5.0 to 12.0) with sensitivity, specificity, and summary area under the curve of 0.73 (95% CI 0.67 to 0.78), 0.74 (0.66 to 0.81), and 0.78 (95% CI 0.74 to 0.82) respectively.
Conclusion: Procalcitonin has good discriminatory power for predicting mortality and disease severity in COVID-19 patients. Therefore, procalcitonin measurement may help identify potentially severe cases and thus decrease mortality by offering early aggressive treatment.